Impact of tumor size on outcome after stereotactic body radiation therapy for inoperable hepatocellular carcinoma
Stereotactic body radiation therapy (SBRT) for inoperable hepatocellular carcinoma (HCC) offers excellent local control rates. This study retrospectively analyzed the influence of different tumor size on treatment outcomes after SBRT.Between December 2008 and February 2014, 141 HCC patients were tre...
Gespeichert in:
| Veröffentlicht in: | Medicine (Baltimore) 2017-12, Vol.96 (50), p.e9249-e9249 |
|---|---|
| Hauptverfasser: | , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | e9249 |
|---|---|
| container_issue | 50 |
| container_start_page | e9249 |
| container_title | Medicine (Baltimore) |
| container_volume | 96 |
| creator | Kuo, Hsing-Tao Que, Jenny Lin, Li-Ching Yang, Ching-Chieh Koay, Lok-Beng Lin, Chia-Hui |
| description | Stereotactic body radiation therapy (SBRT) for inoperable hepatocellular carcinoma (HCC) offers excellent local control rates. This study retrospectively analyzed the influence of different tumor size on treatment outcomes after SBRT.Between December 2008 and February 2014, 141 HCC patients were treated with Cyberknife SBRT. Patients were divided into 3 groups namely small tumors (≤4 cm), intermediate-sized (>4- |
| doi_str_mv | 10.1097/MD.0000000000009249 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_5815772</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>1993999904</sourcerecordid><originalsourceid>FETCH-LOGICAL-c4500-1964a933b4d350646ff3f99f80fd79733ff9c643cb02987bdff4f58e5adec9fa3</originalsourceid><addsrcrecordid>eNpdUU1vFSEUJcbGvlZ_gYlh6Wbq5WvmsTExrdYmbbrRNWEYcFBmmAJj8_z1Ul9t2t4F5HLPOXA4CL0lcEJAdh-uzk7gUUnK5Qu0IYK1jZAtf4k2AFQ0nez4ITrK-ScAYR3lr9AhlUwCa2GDbi6mRZuCo8NlnWLC2f-xOM44rsXEyWLtiq2ndbGxVKQ3uI_DDic9eF18RZbRJr3ssKtsP8eldn2weLSLLtHYENagEzY6mTqd9Gt04HTI9s39foy-f_n87fRrc3l9fnH66bIxXAA0pFrQkrGeD0xAy1vnmJPSbcEN1RJjzknTcmZ6oHLb9YNz3ImtFXqwRjrNjtHHve6y9pMdjJ1L0kEtyU867VTUXj2dzH5UP-JvJbZEdB2tAu_vBVK8WW0uavL5zo-ebVyzIrL-Yi3gFcr2UJNizsm6h2sIqLuw1NWZeh5WZb17_MIHzv90KoDvAbcx1ADyr7De2qRGq0MZ_-mJTtKGAukIJQKamjAB9hdWGaL5</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1993999904</pqid></control><display><type>article</type><title>Impact of tumor size on outcome after stereotactic body radiation therapy for inoperable hepatocellular carcinoma</title><source>Wolters Kluwer Open Health</source><source>MEDLINE</source><source>DOAJ Directory of Open Access Journals</source><source>IngentaConnect Free/Open Access Journals</source><source>Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals</source><source>PubMed Central</source><source>Alma/SFX Local Collection</source><creator>Kuo, Hsing-Tao ; Que, Jenny ; Lin, Li-Ching ; Yang, Ching-Chieh ; Koay, Lok-Beng ; Lin, Chia-Hui</creator><creatorcontrib>Kuo, Hsing-Tao ; Que, Jenny ; Lin, Li-Ching ; Yang, Ching-Chieh ; Koay, Lok-Beng ; Lin, Chia-Hui</creatorcontrib><description>Stereotactic body radiation therapy (SBRT) for inoperable hepatocellular carcinoma (HCC) offers excellent local control rates. This study retrospectively analyzed the influence of different tumor size on treatment outcomes after SBRT.Between December 2008 and February 2014, 141 HCC patients were treated with Cyberknife SBRT. Patients were divided into 3 groups namely small tumors (≤4 cm), intermediate-sized (>4-<10 cm), and large (≥10 cm) tumors. Treatment outcomes, prognoses, and safety at each tumor size were compared and analyzed.A total of 52 patients with small tumors, 55 with intermediate tumors, and 34 patients with large tumors were retrospectively analyzed with a median follow-up of 16 months. Objective responses were achieved at 96.15%, 90.90%, and 76.47% for small, intermediate, and large tumors, respectively (P ≤ .0001) and the 3-year local control rates were 97.85%, 71.99%, and 82.14%, respectively (P = .0035). The 3-year overall survival rates were 50.26%, 45.29%, and 33.38% for small, intermediate, and large tumors, respectively (P = .3757). No significant differences were found in overall-survival, intra-hepatic recurrence free survival, disease-progression free survival, or distant metastasis-free survival.SBRT offers the best effective local control rate and response rate for small HCCs. However, tumor size did not significantly affect the overall survival rate, intra-hepatic recurrence free rate, or disease-progression free rate.</description><identifier>ISSN: 0025-7974</identifier><identifier>EISSN: 1536-5964</identifier><identifier>DOI: 10.1097/MD.0000000000009249</identifier><identifier>PMID: 29390360</identifier><language>eng</language><publisher>United States: The Authors. Published by Wolters Kluwer Health, Inc. All rights reserved</publisher><subject>Carcinoma, Hepatocellular - pathology ; Carcinoma, Hepatocellular - radiotherapy ; Female ; Humans ; Liver Neoplasms - pathology ; Liver Neoplasms - radiotherapy ; Male ; Middle Aged ; Observational Study ; Radiosurgery ; Retrospective Studies ; Treatment Outcome ; Tumor Burden</subject><ispartof>Medicine (Baltimore), 2017-12, Vol.96 (50), p.e9249-e9249</ispartof><rights>The Authors. Published by Wolters Kluwer Health, Inc. All rights reserved.</rights><rights>Copyright © 2017 The Authors. Published by Wolters Kluwer Health, Inc. All rights reserved.</rights><rights>Copyright © 2017 the Author(s). Published by Wolters Kluwer Health, Inc. 2017</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c4500-1964a933b4d350646ff3f99f80fd79733ff9c643cb02987bdff4f58e5adec9fa3</citedby><cites>FETCH-LOGICAL-c4500-1964a933b4d350646ff3f99f80fd79733ff9c643cb02987bdff4f58e5adec9fa3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC5815772/pdf/$$EPDF$$P50$$Gpubmedcentral$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC5815772/$$EHTML$$P50$$Gpubmedcentral$$Hfree_for_read</linktohtml><link.rule.ids>230,314,723,776,780,860,881,27901,27902,53766,53768</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/29390360$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Kuo, Hsing-Tao</creatorcontrib><creatorcontrib>Que, Jenny</creatorcontrib><creatorcontrib>Lin, Li-Ching</creatorcontrib><creatorcontrib>Yang, Ching-Chieh</creatorcontrib><creatorcontrib>Koay, Lok-Beng</creatorcontrib><creatorcontrib>Lin, Chia-Hui</creatorcontrib><title>Impact of tumor size on outcome after stereotactic body radiation therapy for inoperable hepatocellular carcinoma</title><title>Medicine (Baltimore)</title><addtitle>Medicine (Baltimore)</addtitle><description>Stereotactic body radiation therapy (SBRT) for inoperable hepatocellular carcinoma (HCC) offers excellent local control rates. This study retrospectively analyzed the influence of different tumor size on treatment outcomes after SBRT.Between December 2008 and February 2014, 141 HCC patients were treated with Cyberknife SBRT. Patients were divided into 3 groups namely small tumors (≤4 cm), intermediate-sized (>4-<10 cm), and large (≥10 cm) tumors. Treatment outcomes, prognoses, and safety at each tumor size were compared and analyzed.A total of 52 patients with small tumors, 55 with intermediate tumors, and 34 patients with large tumors were retrospectively analyzed with a median follow-up of 16 months. Objective responses were achieved at 96.15%, 90.90%, and 76.47% for small, intermediate, and large tumors, respectively (P ≤ .0001) and the 3-year local control rates were 97.85%, 71.99%, and 82.14%, respectively (P = .0035). The 3-year overall survival rates were 50.26%, 45.29%, and 33.38% for small, intermediate, and large tumors, respectively (P = .3757). No significant differences were found in overall-survival, intra-hepatic recurrence free survival, disease-progression free survival, or distant metastasis-free survival.SBRT offers the best effective local control rate and response rate for small HCCs. However, tumor size did not significantly affect the overall survival rate, intra-hepatic recurrence free rate, or disease-progression free rate.</description><subject>Carcinoma, Hepatocellular - pathology</subject><subject>Carcinoma, Hepatocellular - radiotherapy</subject><subject>Female</subject><subject>Humans</subject><subject>Liver Neoplasms - pathology</subject><subject>Liver Neoplasms - radiotherapy</subject><subject>Male</subject><subject>Middle Aged</subject><subject>Observational Study</subject><subject>Radiosurgery</subject><subject>Retrospective Studies</subject><subject>Treatment Outcome</subject><subject>Tumor Burden</subject><issn>0025-7974</issn><issn>1536-5964</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2017</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNpdUU1vFSEUJcbGvlZ_gYlh6Wbq5WvmsTExrdYmbbrRNWEYcFBmmAJj8_z1Ul9t2t4F5HLPOXA4CL0lcEJAdh-uzk7gUUnK5Qu0IYK1jZAtf4k2AFQ0nez4ITrK-ScAYR3lr9AhlUwCa2GDbi6mRZuCo8NlnWLC2f-xOM44rsXEyWLtiq2ndbGxVKQ3uI_DDic9eF18RZbRJr3ssKtsP8eldn2weLSLLtHYENagEzY6mTqd9Gt04HTI9s39foy-f_n87fRrc3l9fnH66bIxXAA0pFrQkrGeD0xAy1vnmJPSbcEN1RJjzknTcmZ6oHLb9YNz3ImtFXqwRjrNjtHHve6y9pMdjJ1L0kEtyU867VTUXj2dzH5UP-JvJbZEdB2tAu_vBVK8WW0uavL5zo-ebVyzIrL-Yi3gFcr2UJNizsm6h2sIqLuw1NWZeh5WZb17_MIHzv90KoDvAbcx1ADyr7De2qRGq0MZ_-mJTtKGAukIJQKamjAB9hdWGaL5</recordid><startdate>20171201</startdate><enddate>20171201</enddate><creator>Kuo, Hsing-Tao</creator><creator>Que, Jenny</creator><creator>Lin, Li-Ching</creator><creator>Yang, Ching-Chieh</creator><creator>Koay, Lok-Beng</creator><creator>Lin, Chia-Hui</creator><general>The Authors. Published by Wolters Kluwer Health, Inc. All rights reserved</general><general>Wolters Kluwer Health</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><scope>5PM</scope></search><sort><creationdate>20171201</creationdate><title>Impact of tumor size on outcome after stereotactic body radiation therapy for inoperable hepatocellular carcinoma</title><author>Kuo, Hsing-Tao ; Que, Jenny ; Lin, Li-Ching ; Yang, Ching-Chieh ; Koay, Lok-Beng ; Lin, Chia-Hui</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c4500-1964a933b4d350646ff3f99f80fd79733ff9c643cb02987bdff4f58e5adec9fa3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2017</creationdate><topic>Carcinoma, Hepatocellular - pathology</topic><topic>Carcinoma, Hepatocellular - radiotherapy</topic><topic>Female</topic><topic>Humans</topic><topic>Liver Neoplasms - pathology</topic><topic>Liver Neoplasms - radiotherapy</topic><topic>Male</topic><topic>Middle Aged</topic><topic>Observational Study</topic><topic>Radiosurgery</topic><topic>Retrospective Studies</topic><topic>Treatment Outcome</topic><topic>Tumor Burden</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Kuo, Hsing-Tao</creatorcontrib><creatorcontrib>Que, Jenny</creatorcontrib><creatorcontrib>Lin, Li-Ching</creatorcontrib><creatorcontrib>Yang, Ching-Chieh</creatorcontrib><creatorcontrib>Koay, Lok-Beng</creatorcontrib><creatorcontrib>Lin, Chia-Hui</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Medicine (Baltimore)</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Kuo, Hsing-Tao</au><au>Que, Jenny</au><au>Lin, Li-Ching</au><au>Yang, Ching-Chieh</au><au>Koay, Lok-Beng</au><au>Lin, Chia-Hui</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Impact of tumor size on outcome after stereotactic body radiation therapy for inoperable hepatocellular carcinoma</atitle><jtitle>Medicine (Baltimore)</jtitle><addtitle>Medicine (Baltimore)</addtitle><date>2017-12-01</date><risdate>2017</risdate><volume>96</volume><issue>50</issue><spage>e9249</spage><epage>e9249</epage><pages>e9249-e9249</pages><issn>0025-7974</issn><eissn>1536-5964</eissn><abstract>Stereotactic body radiation therapy (SBRT) for inoperable hepatocellular carcinoma (HCC) offers excellent local control rates. This study retrospectively analyzed the influence of different tumor size on treatment outcomes after SBRT.Between December 2008 and February 2014, 141 HCC patients were treated with Cyberknife SBRT. Patients were divided into 3 groups namely small tumors (≤4 cm), intermediate-sized (>4-<10 cm), and large (≥10 cm) tumors. Treatment outcomes, prognoses, and safety at each tumor size were compared and analyzed.A total of 52 patients with small tumors, 55 with intermediate tumors, and 34 patients with large tumors were retrospectively analyzed with a median follow-up of 16 months. Objective responses were achieved at 96.15%, 90.90%, and 76.47% for small, intermediate, and large tumors, respectively (P ≤ .0001) and the 3-year local control rates were 97.85%, 71.99%, and 82.14%, respectively (P = .0035). The 3-year overall survival rates were 50.26%, 45.29%, and 33.38% for small, intermediate, and large tumors, respectively (P = .3757). No significant differences were found in overall-survival, intra-hepatic recurrence free survival, disease-progression free survival, or distant metastasis-free survival.SBRT offers the best effective local control rate and response rate for small HCCs. However, tumor size did not significantly affect the overall survival rate, intra-hepatic recurrence free rate, or disease-progression free rate.</abstract><cop>United States</cop><pub>The Authors. Published by Wolters Kluwer Health, Inc. All rights reserved</pub><pmid>29390360</pmid><doi>10.1097/MD.0000000000009249</doi><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0025-7974 |
| ispartof | Medicine (Baltimore), 2017-12, Vol.96 (50), p.e9249-e9249 |
| issn | 0025-7974 1536-5964 |
| language | eng |
| recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_5815772 |
| source | Wolters Kluwer Open Health; MEDLINE; DOAJ Directory of Open Access Journals; IngentaConnect Free/Open Access Journals; Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals; PubMed Central; Alma/SFX Local Collection |
| subjects | Carcinoma, Hepatocellular - pathology Carcinoma, Hepatocellular - radiotherapy Female Humans Liver Neoplasms - pathology Liver Neoplasms - radiotherapy Male Middle Aged Observational Study Radiosurgery Retrospective Studies Treatment Outcome Tumor Burden |
| title | Impact of tumor size on outcome after stereotactic body radiation therapy for inoperable hepatocellular carcinoma |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-12T18%3A15%3A17IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Impact%20of%20tumor%20size%20on%20outcome%20after%20stereotactic%20body%20radiation%20therapy%20for%20inoperable%20hepatocellular%20carcinoma&rft.jtitle=Medicine%20(Baltimore)&rft.au=Kuo,%20Hsing-Tao&rft.date=2017-12-01&rft.volume=96&rft.issue=50&rft.spage=e9249&rft.epage=e9249&rft.pages=e9249-e9249&rft.issn=0025-7974&rft.eissn=1536-5964&rft_id=info:doi/10.1097/MD.0000000000009249&rft_dat=%3Cproquest_pubme%3E1993999904%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1993999904&rft_id=info:pmid/29390360&rfr_iscdi=true |